Background/Aims: This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu) and busulfan and cyclophosphamide (BuCy2). Methods: Thirty-eight patients (34 with acute lymphoblastic leukemia and 4 with lymphoblastic lymphoma) were included in the current study. The conditioning regimen was BuCy2 for 14 patients and BuFlu for the remaining 24 patients. Eight and 13 patients were high risk disease in the BuCy2 and BuFlu groups, respectively. Results: The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was 56.5% and 55.2% and that of extensive chronic GVHD 17.0% and 55.6% (p = 0.018) for the BuFlu and BuCy2 groups, respectively. The 3-year relapse rate was 27.8% and 31.4% and 3-year overall survival 34.3% and 46.8% for the BuFlu and BuCy2 groups, respectively. Treatment-related mortality (TRM) was significantly lower in the BuFlu group (16.9%) than in the BuCy2 group (57.1%, p = 0.010). In multivariate analyses, the BuFlu regimen was identified as an independent favorable risk factor for TRM (hazard ratio [HR], 0.036; p = 0.017) and extensive chronic GVHD (HR, 0.168; p = 0.034). Conclusions: Our BuFlu regimen would appear to be an acceptable conditioning option for lymphoid malignancies, including high-risk diseases. It was safely administered with a lower TRM rate than BuCy2 conditioning.
INTRODUCTION
Chemotherapy-based conditioning is widely used for myeloid leukemia due to its ease of administration, reduced incidence of long-term sequelae compared to total body irradiation (TBI) conditioning, and equivalent transplantation outcomes with regard to treatment-related mortality (TRM), relapse, and leukemia-free survival (EBMT) and Center for International Blood and Marrow Transplant Research (IBMTR) that demonstrated the equivalence of BuCy2 and CyTBI regimens [1, 2] . However, the major concern with BuCy2 conditioning is the high TRM caused by cyclophosphamide metabolites [8, 9] .
Meanwhile, fludarabine has considerable and synergistic efficacy in both immunosuppression and tumor-cell killing when administered with an alkylating agent, and is widely used as an alternative to cyclophosphamide in reduced-intensity and myeloablative conditioning [10] [11] [12] [13] .
This retrospective study evaluated the transplantation outcomes of patients with adult lymphoid malignancies who received chemotherapy-based conditioning with busulfan and fludarabine (BuFlu), adopted to avoid the sequelae of TBI conditioning and the toxicity of standard BuCy2 conditioning.
METHODS

Patients and transplantation procedures
We retrospectively reviewed the data for 38 patients Cyclosporine was initially administered at a dose of 5.0 mg/kg/day via continuous infusion on the day before the transplantation. The dose was reduced to 2.5 mg/kg/day via continuous infusion on day +7, and then changed to an oral dose of 3 mg/kg twice daily when tolerated. Starting on day 60, the oral cyclosporine dose was reduced by 5%
per week, and then maintained at 1.5 mg/kg/day until day 270 for patients without symptomatic chronic GVHD.
Tacrolimus was administered intravenously at a dose of 0.03 mg/kg/day on the day before transplantation.
Through therapeutic drug monitoring, the blood level of tacrolimus was maintained within the range of [15] [16] [17] [18] [19] [20] ng/mL for the first months and 10-15 ng/mL thereafter.
Patients subsequently received a daily oral dose three to four times higher than the last intravenous dose.
For the purpose of in vivo T cell depletion (TCD), antithymocyte globulin (ATG) was used in patients with HLAmismatched or unrelated donors.
The prophylactic antibiotics consisted of ciprofloxacin (250 mg, twice daily, orally), metronidazole (500 mg, three times daily, orally), and f luconazole (100 mg, once daily, orally) from the initiation of conditioning.
Acyclovir (600 mg, twice daily, orally) was started from day-1 and cotrimoxazole was started after engraftment.
Ursodeoxycholic acid was used for veno-occlusive disease (VOD) prophylaxis from the initiation of conditioning. to -2). For the reduced-intensity BuFlu regimen, busulfan was infused intravenously at a dose of 3.2 mg/kg/day for 2 days (total dose, 6.4 mg/kg; days, -5 to -4); the fludarabine schedule was the same as for the standard BuFlu regimen.
Conditioning regimens
GVHD grading and treatment
Diagnosis and grading of acute GVHD were performed according to the consensus conference guidelines for acute GVHD [14] . The frontline treatment for acute GVHD was the prednisone (1-2 mg/kg/day). In patients with acute GVHD who did not respond to steroids and cyclosporine, cyclosporine was replaced with tacrolimus.
Chronic GVHD was diagnosed and graded based on published criteria [15] . The initial treatment for chronic GVHD was prednisone (1-2 mg/kg/day) and the reintroduction of cyclosporine or tacrolimus in the therapeutic range [16] . If further immunosuppressive agents were needed to control chronic GVHD, the salvage regimen included the use of mycofenolate mofetile (MMF), ATG, weekly MTX, or combination therapy [17, 18] . MMF was added at a dose of 1.5 or 2 g/day and the steroids doses were tapered in refractory cases (by 0.2 mg/kg/wk). The dose of MMF was escalated to 2 g/day in patients with progressive GVHD.
Definitions
The day of stem cell infusion was defined as day 0.
Myeloid engraftment was defined as the first day of a period of at least three consecutive days with an absolute 
Statistical analysis
Continuous variables were compared using the twosample t test, while categorical data were analyzed using the chi-square test. Overall survival (OS) was defined as the time from transplantation until death from any cause, and was analyzed using a Kaplan-Meyer test. Both groups were compared using a log-rank test or Breslow 
RESULTS
Patient characteristics
Thirty-four patients were diagnosed with ALL and four with lymphoblastic lymphoma. Table 1 .
Survival
The survival rate for all patients at 3 years was 41.8% in three patients (21.4%) in the BuCy2 group and six patients (25.0%) in the BuFlu group (p = 0.803) ( Table 2 ). The cumulative incidence of 3-year relapse for the BuCy2 and BuFlu groups was 27.8% and 31.4%, respectively (p = 0.476) (Fig. 3) .
Graft-versus-host disease
The incidence of acute GVHD did not differ between the two groups. Grade II-IV acute GVHD developed in 7 Table 2 ). The cumulative incidence of grade II-IV acute GVHD 100 days after transplantation was 56.5% in the BuCy2 group and 55.2% in the BuFlu group (p = 0.130) (Fig. 4) . Among patients who survived longer than 3 months after transplantation, limited and extensive chronic GVHD developed in two (22.2%) and five (55.6%) patients, respectively, in the BuCy2 group, and in six (35.3%) and two (11.8%) patients, respectively, in the BuFlu group (p = 0.054) ( Table 2 ). The cumulative incidence of extensive chronic GVHD after transplantation in the BuFlu group (17.0%) was lower than that in the BuCy2 group (55.6%; p = 0.018) (Fig. 4) . In univariate analyses, complete remission (CR) (hazard ratio [HR], 3.999; p = 0.077), the BuFlu regimen (HR, 0.168; p = 0.034), and hyperacute GVHD (HR, 5.847; p = 0.054) were identified as factors affecting TRM. Meanwhile, multivariate analysis identified the BuFlu regimen (HR, 0.144; 95% CI, 0.026 to 0.803; p = 0.027) as an independent favorable risk factor for the development of extensive chronic GVHD (Table 3) .
Treatment-related mortality
TRM affected eight patients (57.1%) in the BuCy2 group and three patients (12.5%) in the BuFlu group (p = 0.008) ( Table 2 ). The cumulative incidence of TRM was significantly lower in the BuFlu group (16.9%) than in the BuCy2 group (57.1%, p = 0.010) (Fig. 3) . Causes of TRM in the BuCy2 group included infection (two patients, 14.3%), chronic GVHD (two, 14.3%), VOD (two, 14.3%), and brain hemorrhage (two, 14.3%); in the BuFlu group, they included infection (two patients, 8.3%) and VOD (one, 4.2%).
In univariate analyses, the BuFlu regimen (HR, 0.201; p = 0.018), VOD (HR, 3.931; p = 0.031), and hyperacute GVHD (HR, 3.232; p = 0.062) were identified as significant factors affecting TRM. Multivariate analysis identified the BuFlu regimen (HR, 0.199; 95% CI, 0.052 to 0.752; p = 0.017) as an independent favorable risk factor for TRM, and VOD (HR, 3.951; 95% CI, 1.148 to 13.598; p = 0.029) as an unfavorable risk factor for TRM (Table 4) .
Extramedullary disease
Among the six patients who presented with extramedullary involvement at the time of diagnosis, the five A B Figure 4 . Graft-versus-host disease (GVHD) according to conditioning regimen. (A) Cumulative incidence of grade II-IV acute GVHD. The cumulative incidence of grade II-IV acute GVHD at 100 days after transplantation was 56.5% for the busulfan-cyclophosphamide (BuCy2) group and 55.2% for the busulfan-fludarabine (BuFlu) group. (B) Cumulative incidence of extensive chronic GVHD. Among patients who survived longer than 3 months after transplantation, the cumulative incidence of extensive chronic GVHD after transplantation was lower in the BuFlu group (17.0%) than in the BuCy2 group (55.6%). GVHD, graft-versus-host disease; HR, hazard ratio; CI, confidence interval; LL, lymphoblastic lymphoma; ALL, acute lymphoblastic lymphoma; IP type, immunophenotype; CG, cytogenetic; LDH, lactate dehydrogenase; EM, extramedullary; CR, complete remission; RIC, reduced-intensity conditioning; MA, myeloablative; BuFlu, busulfan-fludarabine; BuCy2, busulfan-cyclophosphamide; CSA, cyclosporine; BM, bone marrow; PBSC, peripheral blood stem cells; TCD, T-cell depletion; HLA, human leukocyte antigen; VOD, venoocclusive disease; CMV, cytomegalovirus; haGVHD, hyperacute GVHD; aGVHD, acute GVHD.
for adult patients with ALL. Moreover, there have been conflicting outcomes [1] [2] [3] [4] [5] .
In the current study, when using non-TBI-based conditioning, the survival rate was comparable to that reported in previous studies, with an overall 3-year OS rate of 41.8% (53.8% for the standard-risk patients and 30.6% for the high-risk patients) (Fig. 1) . Meanwhile, patients with chronic GVHD showed a better survival rate than those without chronic GVHD, demonstrating the strong anti-leukemia effect of GVHD. These results are supported by the results of the subgroup analysis in the EBMT trial, which found no significant differences between patients treated with BuCy2 and those treated with CyTBI in terms of TRM, the incidence of relapse, or LFS [1] . LFS among allograft recipients with intermediaterisk ALL was 43 ± 6% in the BuCy2 group and 33 ± 6% in the CyTBI group, a difference that was not statistically significant. However, there remains some controversy over the role of non-TBI conditioning in ALL patients.
BuCy2 has been used in adult patients with ALL and has an LFS rate that is comparable to those of radiationcontaining regimens [19] . In contrast, in a study conducted by Granados et al. [20] , TBI was associated with a lower relapse rate and better EFS than a busulfan-based conditioning regimen. However, it is difficult to compare the results directly because Granados et al. [20] included some childhood ALL cases, which might have affected the outcomes, and used oral busulfan instead of IV busulfan. The inferior survival rate for BuCy2 patients, especially children, was likely due to the oral busulfan used in these trials. The intestinal absorption of oral busulfan is unpredictable, causing inter-patient variability in the plasma concentration. Moreover, the total plasma clearance rate is two to four times higher in children than in adults [21] [22] [23] [24] [25] . In contrast, intravenous preparations of busulfan produce a more predictable steady-state concentration, resulting in a lower incidence of hepatic VOD and better 100-day survival [26] . Experience with fludarabine-containing conditioning for adult ALL patients is very limited. In a study by Iravani et al. [13] using a myeloablative BuFlu conditioning regimen, the 1-year OS for ALL patients was 55.6%, with a 33.3% relapse rate at 1 year. In the current study, the outcomes for BuFlu conditioning were comparable to those for BuCy2 in terms of OS, EFS, and incidence of relapse (Figs. 2 and 3) . The cumulative incidence of extensive chronic GVHD was significantly lower in the BuFlu group than in the BuCy2 group. Indeed, the BuFlu regimen was an independent favorable risk factor for the development of extensive chronic GVHD. In addition, while the higher relative incidence of TRM remains a major concern for patients receiving BuCy2 conditioning [12, 13] , this was not a significant issue for patients who received BuFlu conditioning (Table 4) . However, interpretation of the current results requires caution because the disease status before transplantation was different in the two groups and, as BuFlu conditioning was performed more recently, improvements in supportive care may have contributed to the favorable outcome regarding TRM in the BuFlu group. CR1 was achieved in more patients in the BuFlu group (75.0%) than in the BuCy2 group (42.9%). Moreover, although only a small number of patients with the Philadelphia chromosome were included in the current study, tyrosine kinase inhibitors were used in more patients in the BuFlu group. In terms of conditioning intensity, RIC in the BuFlu group also confounded the difference in incidence of GVHD between the groups [27] . In addition, to achieve more meaningful results requires analysis of the data after distinguishing between sibling and unrelated donors and a larger sample size.
The major c onc er n w it h chemot herapy-ba sed conditioning in ALL is overcoming the blood-brain barrier. Bunin et al. [6] reported 5 cases of extramedullary relapse (23.8%) with BuCy2 and 2 cases of testicular relapse (9.1%) with TBI, but only 1 case of CNS relapse out of 52 patients who followed a BuCy2 regimen, this patient having previously received cranial irradiation to treat multiply relapsed CNS leukemia [6] . Meanwhile, in the present study, extramedullary relapse in the CNS was only observed in 2 of the 32 patients without extramedullary involvement at presentation, and both of these patients had complex cytogenetic abnormalities at presentation and exhibited no evidence of chronic GVHD after transplantation. Recent studies have indicated that the graft-versus-leukemia (GVL) effect may play a significant role in preventing CNS relapse in patients with lymphoid malignancies who only receive chemotherapy-based conditioning for allogeneic transplantation [28] . In the international collaborative trial conducted by Goldstone et al. [29] (MRC UKALL XII/ECOG E2993), the 5-year OS rate for adult ALL patients was 53% for standardrisk patients and 41% for high-risk patients, while the 5-year relapse rate was 24% for standard-risk patients and 37% for high-risk patients, leading to speculation that allogeneic transplantation has the most potent antileukemic effect in adult ALL, as demonstrated by the significantly reduced relapse rate (37% with a donor vs.
63% without a donor, p < 0.001).
In conclusion, our BuFlu regimen would appear to be an acceptable conditioning option for lymphoid malignancies, including high-risk cases, in terms of OS and EFS. It was safely administered with a lower TRM rate compared to BuCy2 conditioning. When considering the graftversus-leukemia effect, sanctuary site relapse after transplantation would not seem to be a significant issue in patients with lymphoid malignancies.
